
Opinion|Videos|October 9, 2024
mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Key Takeaways
- The Inflation Reduction Act's cost cap will reduce financial burdens, enhancing access to oral chemotherapy for metastatic colorectal cancer patients.
- Improved adherence to prescribed therapies is anticipated due to reduced out-of-pocket expenses, potentially leading to better treatment outcomes.
Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Concerning access to these oral chemotherapy options, how do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will impact access to these metastatic colorectal cancer therapies starting in 2025?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
3
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
4
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
5
















































